Program On Regulation News Today

Panelists at the leading health economics and outcomes conference discuss whether the FDA's process for allowing outside experts to weigh in on drug approvals needs changes.

Fifty-seven percent of drugs granted accelerated approval for a cancer indication showed clinical benefit in confirmatory studies.

The recent launch of direct-to-consumer pharmacy LillyDirect prompts the author of this Viewpoint to consider why it was created and also to raise concerns abou

This cross-sectional study identified the prevalence of patents on risk evaluation and mitigation strategies and their association with delaying generic competi

Researchers suggest an alternative method to align drug prices with clinical benefits for patients with psoriasis.

The most expensive gene therapy on the US market may give payers pause, said study authors.

To lower drug prices, the Biden administration is looking to assert its authority to license drug patents that rely on government-funded research to drugmakers that would offer cheaper medicines.

To lower drug prices, the Biden administration is looking to assert its authority to license drug patents that rely on government-funded research to drugmakers that would offer cheaper medicines.

To lower drug prices, the Biden administration is looking to assert its authority to license drug patents that rely on government-funded research to drugmakers that would offer cheaper medicines.

To lower drug prices, the Biden administration is looking to assert its authority to license drug patents that rely on government-funded research to drugmakers that would offer cheaper medicines.